Hyperflex(R) Balloon Catheter by Endovastec(TM) Receives Marketing Approval in Japan
PR95184
SHANGHAI, March 28, 2022 /PRNewswire=KYODO JBN/ --
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec(TM))
recently announced that it has received registration approval from Japan
Pharmaceuticals and Medical Devices Agency (PMDA) for its
independently-developed Hyperflex(R) Balloon Catheter (Hyperflex(R)) as the
company's first product approved for marketing in Japan. Hyperflex(R) obtained
CE Mark in 2016 and is already available in overseas markets in South America
and Asia.
Hyperflex(R) is intended to assist in the dilation of aortic stent graft. It
uses a compliant TPU balloon to expand the deployed stent graft, which enables
improved adherence to the vascular wall, minimizes type I/III endoleaks, and
improves stent positioning for better short- and long-term outcomes. When used
in conjunction with the aortic stent graft system, Hyperflex(R) provides an
integrated endovascular aneurysm repair(EVAR) solution, making it easier and
more flexible.
Mr. Qing Zhu, President of Endovastec(TM), stated, "The approval of the
Hyperflex(R) Balloon Catheter in Japan signals a growing acceptance of our EVAR
devices in more and more national and regional healthcare systems, paving the
way for the company's continued marketing in Asia and the globe. Endovastec(TM)
will continue to innovate to improve solutions for aortic diseases and reach
more patients worldwide with better products and services."
About Endovastec(TM)
Founded in Shanghai in 2012, Shanghai MicroPort Endovascular MedTech (Group)
Co., Ltd. ("Endovastec(TM)", Stock code: 688016.SH), a subsidiary of MicroPort
Scientific Corporation ("MicroPort(R)", Stock code: 00853.HK), is a global
medical devices company focusing on R&D, manufacturing, and sales of aortic and
peripheral vascular interventional devices, with main products of thoracic and
abdominal aortic stent grafts, stent grafts in surgical operation, drug coated
PTA balloon catheters, and PTA balloon catheters etc. At Endovastec(TM), we are
breaking barriers and accelerating access to provide trustworthy and universal
access to state-of-the-art solutions of prolonging and reshaping all lives, and
to build a people centric enterprise ranking as a global leader of evolving and
emerging medical technologies through continuous innovation.
SOURCE: Endovastec
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。